Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ovid Therapeutics (OVID) Profit After Tax (2020 - 2025)

Historic Profit After Tax for Ovid Therapeutics (OVID) over the last 6 years, with Q3 2025 value amounting to -$12.2 million.

  • Ovid Therapeutics' Profit After Tax rose 1289.45% to -$12.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$36.4 million, marking a year-over-year decrease of 1195.96%. This contributed to the annual value of -$26.4 million for FY2024, which is 4949.66% up from last year.
  • Per Ovid Therapeutics' latest filing, its Profit After Tax stood at -$12.2 million for Q3 2025, which was up 1289.45% from -$4.7 million recorded in Q2 2025.
  • In the past 5 years, Ovid Therapeutics' Profit After Tax ranged from a high of $176.0 million in Q1 2021 and a low of -$26.0 million during Q4 2021
  • Its 5-year average for Profit After Tax is -$2.0 million, with a median of -$12.0 million in 2022.
  • As far as peak fluctuations go, Ovid Therapeutics' Profit After Tax soared by 97871.45% in 2021, and later plummeted by 15515.78% in 2025.
  • Quarter analysis of 5 years shows Ovid Therapeutics' Profit After Tax stood at -$26.0 million in 2021, then skyrocketed by 55.75% to -$11.5 million in 2022, then crashed by 33.18% to -$15.3 million in 2023, then surged by 39.61% to -$9.3 million in 2024, then tumbled by 31.85% to -$12.2 million in 2025.
  • Its Profit After Tax stands at -$12.2 million for Q3 2025, versus -$4.7 million for Q2 2025 and -$10.2 million for Q1 2025.